A rumor regarding Seres Therapeutics was highlighted in a “rare alert” issued by Betaville, sources tell The Fly. The M&A-focused blog defines a “rare alert” as “market gossip that has been tested with some of Betaville’s usually well-informed sources… However, the rumour hasn’t been tested through formal journalistic channels.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCRB:
- Seres Therapeutics files to sell 14.29M shares of common stock for holders
- Seres Therapeutics Streamlines Focus with VOWST Sale to Nestlé
- Seres shareholders request clarity from board about possible Nestle offer
- Seres Therapeutics shareholders approve sale of VOWST
- Seres Therapeutics’ SER-155 Shows Promising Clinical Results